181 related articles for article (PubMed ID: 19894726)
1. Fluorinated rhodacyanine (SJL-01) possessing high efficacy for visceral leishmaniasis (VL).
Yang M; Arai C; Bakar Md A; Lu J; Ge JF; Pudhom K; Takasu K; Kasai K; Kaiser M; Brun R; Yardley V; Itoh I; Ihara M
J Med Chem; 2010 Jan; 53(1):368-73. PubMed ID: 19894726
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antileishmanial activity of novel 2,4,6-trisubstituted pyrimidines and 1,3,5-triazines.
Sunduru N; Nishi ; Palne S; Chauhan PM; Gupta S
Eur J Med Chem; 2009 Jun; 44(6):2473-81. PubMed ID: 19217698
[TBL] [Abstract][Full Text] [Related]
3. Potential of doxorubicin as an antileishmanial agent.
Sett R; Basu N; Ghosh AK; Das PK
J Parasitol; 1992 Apr; 78(2):350-4. PubMed ID: 1556650
[TBL] [Abstract][Full Text] [Related]
4. Phase transfer catalyzed synthesis of bis-quinolines: antileishmanial activity in experimental visceral leishmaniasis and in vitro antibacterial evaluation.
Palit P; Paira P; Hazra A; Banerjee S; Gupta AD; Dastidar SG; Mondal NB
Eur J Med Chem; 2009 Feb; 44(2):845-53. PubMed ID: 18538452
[TBL] [Abstract][Full Text] [Related]
5. Eugenol derived immunomodulatory molecules against visceral leishmaniasis.
Charan Raja MR; Velappan AB; Chellappan D; Debnath J; Kar Mahapatra S
Eur J Med Chem; 2017 Oct; 139():503-518. PubMed ID: 28826085
[TBL] [Abstract][Full Text] [Related]
6. Antiparasitic activity of a triphenyl tin complex against Leishmania donovani.
Raychaudhury B; Banerjee S; Gupta S; Singh RV; Datta SC
Acta Trop; 2005 Jul; 95(1):1-8. PubMed ID: 15896700
[TBL] [Abstract][Full Text] [Related]
7. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages.
Paila YD; Saha B; Chattopadhyay A
Biochem Biophys Res Commun; 2010 Aug; 399(3):429-33. PubMed ID: 20678487
[TBL] [Abstract][Full Text] [Related]
8. Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.
Gupta S; Yardley V; Vishwakarma P; Shivahare R; Sharma B; Launay D; Martin D; Puri SK
J Antimicrob Chemother; 2015 Feb; 70(2):518-27. PubMed ID: 25389223
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives.
Mäntylä A; Rautio J; Nevalainen T; Vepsälainen J; Juvonen R; Kendrick H; Garnier T; Croft SL; Järvinen T
Bioorg Med Chem; 2004 Jul; 12(13):3497-502. PubMed ID: 15186834
[TBL] [Abstract][Full Text] [Related]
10. Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani.
Bories C; Cojean S; Huteau F; Loiseau PM
Biomed Pharmacother; 2008 Mar; 62(3):164-7. PubMed ID: 18249083
[TBL] [Abstract][Full Text] [Related]
11. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
Narayan S; Bimal S; Singh SK; Gupta AK; Singh VP; Sinha PK; Das P
Exp Parasitol; 2009 Jan; 121(1):69-75. PubMed ID: 18948098
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
Gopinath VS; Pinjari J; Dere RT; Verma A; Vishwakarma P; Shivahare R; Moger M; Kumar Goud PS; Ramanathan V; Bose P; Rao MV; Gupta S; Puri SK; Launay D; Martin D
Eur J Med Chem; 2013 Nov; 69():527-36. PubMed ID: 24095747
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani.
Nakayama H; Desrivot J; Bories C; Franck X; Figadère B; Hocquemiller R; Fournet A; Loiseau PM
Biomed Pharmacother; 2007; 61(2-3):186-8. PubMed ID: 17360145
[TBL] [Abstract][Full Text] [Related]
14. Leishmania donovani: pilot study for evaluation of therapeutic effects of inosine analogs against amastigotes in vitro and in vivo.
Morishige K; Aji T; Ishii A; Yasuda T; Wataya Y
Exp Parasitol; 1995 Jun; 80(4):665-71. PubMed ID: 7758547
[TBL] [Abstract][Full Text] [Related]
15. Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani.
Kaur J; Sundar S; Singh N
J Antimicrob Chemother; 2010 Aug; 65(8):1742-8. PubMed ID: 20519355
[TBL] [Abstract][Full Text] [Related]
16. β-Amino acid derivatives as mitochondrial complex III inhibitors of L. donovani: A promising chemotype targeting visceral leishmaniasis.
Chandrakar P; Gunaganti N; Parmar N; Kumar A; Singh SK; Rashid M; Wahajuddin M; Mitra K; Narender T; Kar S
Eur J Med Chem; 2019 Nov; 182():111632. PubMed ID: 31499363
[TBL] [Abstract][Full Text] [Related]
17. Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.
Sharief AH; Gasim Khalil EA; Theander TG; Kharazmi A; Omer SA; Ibrahim ME
Exp Parasitol; 2006 Dec; 114(4):247-52. PubMed ID: 16716301
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
[TBL] [Abstract][Full Text] [Related]
19. Antileishmanial and immunomodulatory activities of lupeol, a triterpene compound isolated from Sterculia villosa.
Das A; Jawed JJ; Das MC; Sandhu P; De UC; Dinda B; Akhter Y; Bhattacharjee S
Int J Antimicrob Agents; 2017 Oct; 50(4):512-522. PubMed ID: 28669838
[TBL] [Abstract][Full Text] [Related]
20. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
Sane SA; Shakya N; Haq W; Gupta S
J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
